Adult Acute Myeloid Leukemia

Jabbour, Elias J.; Estey, Elihu; Kantarjian, Hagop M.
February 2006
Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p247
Academic Journal
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging. Standard regimens using cytarabine and anthracyclines for induction followed by some form of postremission therapy produce response rates of 60% to 70%, with less than 20% of all patients achieving long-term disease-free survival. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Such targeted therapies offer the promise of better antileukemic activity in adult AML.


Related Articles

  • Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Bacher, U; Hochhaus, A; Berger, U; Hiddemann, W; Hehlmann, R; Haferlach, T; Schoch, C // Leukemia (08876924);Mar2005, Vol. 19 Issue 3, p460 

    This article reports that CEBP mutations have been described in adult acute myeloid leukemia. Patients with CEBP mutations were also analyzed for activation mutations of FLT3-ITD, FLT3-TKD and N-ras. In the 116 patients examined, FLT3-ITD mutations were detected in two of the even patients with...

  • A new player SETs in myeloid malignancy. Trimarchi, Thomas; Ntziachristos, Panagiotis; Aifantis, Iannis // Nature Genetics;Aug2013, Vol. 45 Issue 8, p846 

    Recent studies have identified recurrent mutations in SETBP1, the gene that encodes SET-binding protein 1, in several types of myeloid malignancies, including chronic myeloid and acute myeloid leukemias. The identified mutations frequently target the SKI-homologous domain, although the exact...

  • Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Rapoport, A. P.; Levine, B. L.; Badros, A.; Meisenberg, B.; Ruehle, K.; Nandi, A; Rollins, S.; Natt, S.; Ratterree, B.; Westphal, S.; Mann, D.; June, C. H. // Bone Marrow Transplantation;Jan2004, Vol. 33 Issue 1, p53 

    Summary:Four patients with chronic myelogenous leukemia (CML) that was refractory to interferon alpha (two patients) or imatinib mesylate (two patients), and who lacked donors for allogeneic stem cell transplantation, received autotransplants followed by infusions of ex vivo costimulated...

  • Genome-Wide Analysis of Transcriptional Reprogramming in Mouse Models of Acute Myeloid Leukaemia. Bonadies, Nicolas; Foster, Samuel D.; Wai-In Chan; Kvinlaug, Brynn T.; Spensberger, Dominik; Dawson, Mark A.; Spooncer, Elaine; Whetton, Anthony D.; Bannister, Andrew J.; Huntly, Brian J.; Gƶttgens, Berthold // PLoS ONE;2011, Vol. 6 Issue 1, p1 

    Acute leukaemias are commonly caused by mutations that corrupt the transcriptional circuitry of haematopoietic stem/ progenitor cells. However, the mechanisms underlying large-scale transcriptional reprogramming remain largely unknown. Here we investigated transcriptional reprogramming at...

  • A Confused 55-Year-Old Man. Pitchford, Clovis W.; Welch, Derek C. // Archives of Pathology & Laboratory Medicine;Apr2006, Vol. 130 Issue 4, p567 

    We present a case of a 55-year-old man with acute myeloid leukemia status after bone marrow transplantation who developed multiorgan failure and died within a week of the onset of symptoms. A postmortem examination revealed disseminated toxoplasmosis. We discuss the clinical presentation,...

  • Clinical and biological features of favorable-risk acute myelogenous leukemia-is favorable-risk AML really favorable? Schiller, G. J // Leukemia (08876924);Mar2005, Vol. 19 Issue 3, p326 

    This article focuses on acute myelogenous leukemia. It is a complex and heterogeneous disease characterized by an arrest of normal hematopoetic maturation produced by a clone of karyotypically distinct neoplastic cells. In the early 1980s, acute myelomonocytic leukemia with abnormal eosinophils...

  • Utility of a multiplex reverse transcriptasepolymerase chain reaction assay (HemaVision) in the evaluation of genetic abnormalities in Korean children with acute leukemia: a single institution study. Hye-Jin Kim; Hyun Jin Oh; Jae Wook Lee; Pil-Sang Jang; Nack-Gyun Chung; Myungshin Kim; Jihyang Lim; Bin Cho; Hack-Ki Kim // Korean Journal of Pediatrics;Jun2013, Vol. 56 Issue 6, p247 

    Purpose: In children with acute leukemia, bone marrow genetic abnormalities (GA) have prognostic significance, and may be the basis for minimal residual disease monitoring. Since April 2007, we have used a multiplex reverse transcriptase-polymerase chain reaction tool (HemaVision) to detect of...

  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes. Vardiman, James; Reichard, Kaaren // American Journal of Clinical Pathology;Jul2015, Vol. 144 Issue 1, p29 

    Objectives: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous disorder defined by morphologic, genetic, or clinical features. Genetic abnormalities associated with AML-MRC are often associated with adverse prognostic features, and many cases are preceded by...

  • The biological behavior of SDF-1/CXCR4 in patients with myelodysplastic syndrome. Yang, Rui; Pu, Jie; Guo, Juan; Xu, Feng; Zhang, Zheng; Zhao, Youshan; Zhang, Xi; Gu, ShuCheng; Chang, ChunKang; Li, Xiao // Medical Oncology;Jun2012, Vol. 29 Issue 2, p1202 

    The purpose of this investigation is to evaluate the biological behavior of stromal cell-derived factor-l (SDF-1) in migration, adhesion, and apoptosis as well as the related signaling transduction pathways in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics